• Above all, we make a difference.
  • Treatment References


    1. Howlader N, Noone AM, Krapcho M, et al., editors. SEER Fast Stats, 1975-2013. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/faststats/, 2016.
    2. DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 64(4):252-71, 2014.
    3. Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 59(1):56-66, 2009.
    4. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 347(16):1233-41, 2002.
    5. Darby S, McGale P, Correa C, et al. for the Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 378(9804):1707-16, 2011.
    6. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 305(6):569-75, 2011.
    7. Galimberti V, Cole BF, Zurrida S, et al. for the International Breast Cancer Study Group Trial 23-01 investigators. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 14(4):297-305, 2013.
    8. Agresti R, Martelli G, Sandri M, et al. Axillary lymph node dissection versus no dissection in patients with T1N0 breast cancer: A randomized clinical trial (INT09/98). Cancer. 120(6):885-93, 2014.
    9. Smith GL, Xu Y, Shih YC, et al. Breast-conserving surgery in older patients with invasive breast cancer: current patterns of treatment across the United States. J Am Coll Surg. 209(4):425-433.e2, 2009.
    10. The Dartmouth Atlas of Health Care. Inpatient mastectomy for cancer. http://www.dartmouthatlas.org/data/table.aspx?ind=95, 2012.
    11. Habermann EB, Abbott A, Parsons HM, Virnig BA, Al-Refaie WB, Tuttle TM. Are mastectomy rates really increasing in the United States? J Clin Oncol. 28(21):3437-41, 2010.
    12. Enewold L, Zhou J, McGlynn KA, et al. Racial variation in tumor stage at diagnosis among Department of Defense beneficiaries. Cancer. 118(3):812-20, 2012.
    13. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Breast cancer V.1.2016. http://www.nccn.org/, 2016.
    14. Harris JR and Morrow M. Chapter 35: Breast-conserving surgery, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
    15. National Cancer Institute. Radiation therapy and you: support for people with cancer. http://www.cancer.gov/publications/patient-education/radiationttherapy.pdf, 2012.
    16. DiSipio T, Rye S, Newman B, Hayes S. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol. 14(6):500-15, 2013.
    17. National Cancer Institute. General information about lymphedema. http://www.cancer.gov/about-cancer/treatment/side-effects/lymphedema/lymphedema-pdq, 2015.
    18. Kirova YM, De Rycke Y, Gambotti L, Pierga J-Y, Asselain B, Fourquet A for the Institut Curie Breast Cancer Study Group. Second malignancies after breast cancer: the impact of different treatment modalities. Br J Cancer. 98(5):870-4, 2008.
    19. Mery CM, George S, Bertagnolli MM, Raut CP. Secondary sarcomas after radiotherapy for breast cancer: sustained risk and poor survival. Cancer. 115(18):4055-63, 2009.
    20. Shah C, Antonucci JV, Wilkinson JB, et al. Twelve-year clinical outcomes and patterns of failure with accelerated partial breast irradiation versus whole-breast irradiation: results of a matched-pair analysis. Radiother Oncol. 100(2):210-4, 2011.
    21. Hattangadi JA, Powell SN, MacDonald SM, et al. Accelerated partial breast irradiation with low-dose-rate interstitial implant brachytherapy after wide local excision: 12-year outcomes from a prospective trial. Int J Radiat Oncol Biol Phys. 83(3):791-800, 2012.
    22. Strnad V, Ott OJ, Hildebrandt G, et al. for the Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet. 387(10015):229-38, 2016.
    23. Shah C, Badiyan S, Ben Wilkinson J, et al. Treatment efficacy with accelerated partial breast irradiation (APBI): final analysis of the American Society of Breast Surgeons MammoSite(®) breast brachytherapy registry trial. Ann Surg Oncol. 20(10):3279-85, 2013.
    24. Ajkay N, Collett AE, Bloomquist EV, Gracely EJ, Frazier TG, Barrio AV. A comparison of complication rates in early-stage breast cancer patients treated with brachytherapy versus whole-breast irradiation. Ann Surg Oncol. 22(4):1140-5, 2015.
    25. Olivotto IA, Whelan TJ, Parpia S, et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. J Clin Oncol. 31(32):4038-45, 2013.
    26. Vaidya JS, Wenz F, Bulsara M, et al. on behalf of the TARGIT trialists' group. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet. 383(9917):603-13, 2014.
    27. Richardson LC, Wang W, Hartzema AG, Wagner S. The role of health-related quality of life in early discontinuation of chemotherapy for breast cancer. Breast J. 13(6):581-7, 2007.
    28. Komen MM, Smorenburg CH, van den Hurk CJ, Nortier JW. Factors influencing the effectiveness of scalp cooling in the prevention of chemotherapy-induced alopecia. Oncologist. 18(7):885-91, 2013.
    29. Cramp F, Byron-Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev. 11:CD006145, 2012.
    30. Fong DY, Ho JW, Hui BP, et al. Physical activity for cancer survivors: meta-analysis of randomised controlled trials. BMJ. 344:e70, 2012.
    31. Escalante CP. Cancer-related fatigue: treatment, in Up-to-Date (Hesketh PJ, Ganz PA, Vora SR, eds.). Up-to-Date, 2015.
    32. National Cancer Institute. Chemotherapy and you: support for people with cancer. http://www.cancer.gov/publications/patient-education/chemotherapy-and-you.pdf, 2011.
    33. Ruddy KJ and Ginsburg ES. Chapter 90: Reproductive issues in breast cancer survivors, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
    34. American College of Obstetricians and Gynecologists' Committee on Gynecologic Practice: Committee Opinion No. 584: oocyte cryopreservation. Obstet Gynecol. 123(1):221-2, 2014.
    35. Stan D, Hershman D, Loprinzi CL. Chapter 51: Management of menopausal symptoms in breast cancer survivors, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
    36. Saquib N, Flatt SW, Natarajan L, et al. Weight gain and recovery of pre-cancer weight after breast cancer treatments: evidence from the women's healthy eating and living (WHEL) study. Breast Cancer Res Treat. 105(2):177-86, 2007.
    37. Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 123(3):627-35, 2010.
    38. Ewertz M, Jensen MB, Gunnarsdóttir KA, et al. Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol. 29(1):25-31, 2011.
    39. Niraula S, Ocana A, Ennis M, Goodwin PJ. Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis. Breast Cancer Res Treat. 134(2):769-81, 2012.
    40. Goedendorp MM, Andrykowski MA, Donovan KA, et al. Prolonged impact of chemotherapy on fatigue in breast cancer survivors: A longitudinal comparison with radiotherapy-treated breast cancer survivors and noncancer controls. Cancer. 118(15):3833-41, 2012.
    41. Jim HS, Phillips KM, Chait S, et al. Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol. 30(29):3578-87, 2012.
    42. Ahles TA, Root JC, Ryan EL. Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol. 30(30):3675-86, 2012.
    43. National Cancer Institute. Managing chemotherapy side effects: Memory changes. http://www.cancer.gov/cancertopics/coping/chemo-side-effects/memory.pdf, 2009.
    44. Azim HA Jr, de Azambuja E, Colozza M, Bines J, Piccart MJ. Long-term toxic effects of adjuvant chemotherapy in breast cancer. Ann Oncol. 22(9):1939-47, 2011.
    45. Wolff AC, Blackford AL, Visvanathan K, et al. Risk of marrow neoplasms after adjuvant breast cancer therapy: the National Comprehensive Cancer Network experience. J Clin Oncol. 33(4):340-8, 2015.
    46. de Azambuja E, Procter MJ, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). J Clin Oncol. 32(20):2159-65, 2014.
    47. Advani PP, Ballman KV, Dockter TJ, Colon-Otero G, Perez EA. Long-term cardiac safety analysis of NCCTG N9831 (Alliance) adjuvant trastuzumab trial. J Clin Oncol. 34(6):581-7, 2016. 
    48. Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet. 378(9805):1812-23, 2011.
    49. Harris LN, Ismaila N, McShane LM, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 12(4):384-9, 2016.
    50. Paterson AH1, Anderson SJ, Lembersky BC, et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol. 13(7):734-42, 2012.
    51. Coleman R, Powles T, Paterson A, et al. for the Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 386(10001):1353-61, 2015.
    52. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol. 19(3):420-32, 2008.
    53. Rathbone EJ, Brown JE, Marshall HC, et al. Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). J Clin Oncol. 31(21):2685-91, 2013.
    54. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 361(2):123-34, 2009.
    55. Majewski IJ, Nuciforo P, Mittempergher L, et al. PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. J Clin Oncol. 33(12):1334-9, 2015.
    56. Pogue-Geile KL, Song N, Jeong JH, et al. Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. J Clin Oncol. 33(12):1340-7, 2015.
    57. Regan MM, Leyland-Jones B, Bouzyk M, et al. on behalf of the Breast International Group (BIG) 1-98 Collaborative Group. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The Breast International Group 1-98 Trial. J Natl Cancer Inst. 104(6):441-451, 2012.
    58. Rae JM, Drury S, Hayes DF, et al. on behalf of the ATAC trialists. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst. 104(6):452-460, 2012.
    59. Kelly CM, Juurlink DN, Gomes T, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ. 340:c693, 2010.
    60. Soliman H. Developing an effective breast cancer vaccine. Cancer Control. 17(3):183-90, 2010.
    61. Davies C, Godwin J, Gray R, et al. for the Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 378(9793):771-84, 2011.
    62. Dowsett M, Forbes JF, Bradley R, et al. for the Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 386(10001):1341-52, 2015.
    63. Murphy B and Muss HB. Hormonal therapy of breast cancer: state of the art. Oncology (Huntingt). 11: 7-13, 1997.
    64. Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer. 108(7):1515-24, 2013.
    65. Davies C, Pan H, Godwin J, et al. for the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 381(9869):805-16, 2013.
    66. Vogel VG, Costantino JP, Wickerham DL, et al. for the National Surgical Adjuvant Breast and Bowel Project. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res. 3(6):696-706, 2010.
    67. Rimawi MF and Osborne CK. Chapter 43: Adjuvant systemic therapy: endocrine therapy, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
    68. Ruddy KJ, Winer EP. Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol. 24(6):1434-43, 2013.
    69. Mouridsen H, Giobbie-Hurder A, Goldhirsch A, et al. for the BIG 1-98 Collaborative Group. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 361(8):766-76, 2009.
    70. Cuzick J, Sestak I, Baum M, et al. for the ATAC/LATTE investigators. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 11(12):1135-41, 2010.
    71. Bliss JM, Kilburn LS, Coleman RE, et al. Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. J Clin Oncol. 30(7):709-17, 2012.
    72. Goss PE, Ingle JN, Alés-Martínez JE, et al. for the NCIC CTG MAP.3 Study Investigators. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 364(25):2381-91, 2011.
    73. Cuzick J, Sestak I, Forbes JF, et al. on behalf of the IBIS-II investigators. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet. 383(9922):1041-8, 2014.
    74. Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 25(25):3877-83, 2007.
    75. Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 103(17):1299-309, 2011.
    76. Dent SF, Gaspo R, Kissner M, Pritchard KI. Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer. Breast Cancer Res Treat. 126(2):295-310, 2011.
    77. Spagnolo F, Sestak I, Howell A, Forbes JF, Cuzick J. Anastrozole-induced carpal tunnel syndrome: results from the International Breast Cancer Intervention Study II Prevention Trial. J Clin Oncol. 34(2):139-43, 2016.
    78. Irwin ML, Cartmel B, Gross CP, et al. Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin Oncol. 33(10):1104-11, 2015.
    79. Briot K, Tubiana-Hulin M, Bastit L, Kloos I, Roux C. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study. Breast Cancer Res Treat. 120(1):127-34, 2010.
    80. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 28(35):5132-9, 2010.
    81. Hadji P, Body JJ, Aapro MS, et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol. 19(8):1407-16, 2008.
    82. Harris SR, Schmitz KH, Campbell KL, McNeely ML. Clinical practice guidelines for breast cancer rehabilitation: syntheses of guideline recommendations and qualitative appraisals. Cancer. 118(8 Suppl):2312-24, 2012.
    83. Pagani O, Regan MM, Walley BA, et al. for the TEXT and SOFT Investigators and the International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 371(2):107-18, 2014.
    84. Francis PA, Regan MM, Fleming GF, et al. for the SOFT Investigators and the International Breast Cancer Study Group. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 372(5):436-46, 2015.
    85. Tevaarwerk AJ, Wang M, Zhao F, et al. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 32(35):3948-58, 2014.
    86. Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology Clinical practice guideline update on ovarian suppression. J Clin Oncol. 34(14):1689-701, 2016.
    87. Sharma R, Hamilton A, Beith J. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane Database Syst Rev. (4):CD004562, 2008.
    88. American Cancer Society. Targeted therapy for breast cancer. http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-treating-targeted-therapy, 2015.
    89. Schott AF. Systemic treatment for HER2-positive metastatic breast cancer, in Up-to-Date (Hayes DF, Vora SR, eds.). Up-to-Date, 2015.
    90. Gianni L, Dafni U, Gelber RD, et al. for the Herceptin Adjuvant (HERA) Trial Study Team. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 12(3):236-244, 2011.
    91. Slamon D, Eiermann W, Robert N, et al. for the Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 365(14):1273-83, 2011.
    92. Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 32(33):3744-52, 2014.
    93. Mieog JSD, van der Hage JA, van de Velde CJH. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg. 94(10):1189-1200, 2007.
    94. Kaufmann M, Morrow M, von Minckwitz G, Harris JR (Biedenkopf Expert Panel Members). Locoregional treatment of primary breast cancer: consensus recommendations from an international expert panel. Cancer. 116(5):1184-91, 2010.
    95. Mamounas EP, Anderson SJ, Dignam JJ, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of national surgical adjuvant breast and bowel project B-18 and B-27. J Clin Oncol. 30(32):3960-6, 2012.
    96. Ellis MJ, Suman VJ, Hoog J, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. J Clin Oncol. 29(17):2342-9, 2011.
    97. U.S. Food and Drug Administration (FDA). FDA approves Perjeta for neoadjuvant breast cancer treatment. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm370393.htm, 2013.
    98. Boughey JC, Suman VJ, Mittendorf EA, et al. for the Alliance for Clinical Trials in Oncology. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 310(14):1455-61, 2013.
    99. Lyman GH. Appropriate role for sentinel node biopsy after neoadjuvant chemotherapy in patients with early-stage breast cancer. J Clin Oncol. 33(3):232-4, 2015.
    100. Hwang ES, Lichtensztajn DY, Gomez SL, Fowble B, Clarke CA. Survival after lumpectomy and mastectomy for early stage invasive breast cancer: the effect of age and hormone receptor status. Cancer. 119(7):1402-11, 2013.
    101. Carlson RW. Chapter 67: Surveillance of patients following primary therapy, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
    102. Arvold ND, Taghian AG, Niemierko A, et al. Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol. 29(29):3885-91, 2011.
    103. Dawood S, Ueno NT, Valero V, et al. Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer. 117(9):1819-26, 2011.
    104. Overmoyer B and Pierce LJ. Chapter 59: Inflammatory Breast Cancer, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition, Lippincott Williams & Wilkins, 2014.
    105. Harris EE, Schultz D, Bertsch H, et al. Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 55(5):1200-8, 2003.
    106. Untch M, Möbus V, Kuhn W, et al. Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol. 27(18):2938-45, 2009.
    107. Yang R, Cheung MC, Hurley J, et al. A comprehensive evaluation of outcomes for inflammatory breast cancer. Breast Cancer Res Treat. 117(3):631-41, 2009.
    108. Tsai CJ, Li J, Gonzalez-Angulo AM, et al. Outcomes after multidisciplinary treatment of inflammatory breast cancer in the era of neoadjuvant HER2-directed therapy. Am J Clin Oncol. 38(3):242-7, 2015.
    109. Mehrara BJ and Ho AY. Chapter 36: Breast reconstruction, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
    110. Zhong T, Hu J, Bagher S, et al. Decision regret following breast reconstruction: the role of self-efficacy and satisfaction with information in the preoperative period. Plast Reconstr Surg. 132(5):724e-734e, 2013.
    111. Olsen MA, Lefta M, Dietz JR, et al. Risk factors for surgical site infection after major breast operation. J Am Coll Surg. 207(3):326-35, 2008.
    112. Fischer JP, Nelson JA, Kovach SJ, Serletti JM, Wu LC, Kanchwala S. Impact of obesity on outcomes in breast reconstruction: analysis of 15,937 patients from the ACS-NSQIP datasets. J Am Coll Surg. 217(4):656-64, 2013.
    113. Matsen CB, Mehrara B, Eaton A, et al. Skin flap necrosis after mastectomy with reconstruction: a prospective study. Ann Surg Oncol. 23(1):257-64, 2016.
    114. Christensen BO, Overgaard J, Kettner LO, Damsgaard TE. Long-term evaluation of postmastectomy breast reconstruction. Acta Oncol. 50(7):1053-61, 2011.
    115. Janowsky EC, Kupper LL, Hulka BS. Meta-analyses of the relation between silicone breast implants and the risk of connective-tissue diseases. N Engl J Med. 342(11):781-90, 2000.
    116. Aladily TN, Medeiros LJ, Amin MB, et al. Anaplastic large cell lymphoma associated with breast implants: a report of 13 cases. Am J Surg Pathol. 36(7):1000-8, 2012.
    117. Center for Devices and Radiological Health, U.S. Food and Drug Administration. Anaplastic large cell lymphoma (ALCL) in women with breast implants: Preliminary FDA findings and analyses. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/BreastImplants/ucm239996.htm, 2013.
    118. Gidengil CA, Predmore Z, Mattke S, van Busum K, Kim B. Breast implant-associated anaplastic large cell lymphoma: a systematic review. Plast Reconstr Surg. 135(3):713-20, 2015.
    119. Lee KT, Mun GH. Updated evidence of acellular dermal matrix use for implant-based breast reconstruction: a meta-analysis. Ann Surg Oncol. 23(2):600-10, 2016.
    120. U.S. Food and Drug Administration (FDA). Risks of breast implants. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/BreastImplants/ucm064106.htm, 2013.
    121. Masoomi H, Clark EG, Paydar KZ, et al. Predictive risk factors of free flap thrombosis in breast reconstruction surgery. Microsurgery. 34(8):589-94, 2014.
    122. LoTempio MM, Allen RJ. Breast reconstruction with SGAP and IGAP flaps. Plast Reconstr Surg. 126(2):393-401, 2010.
    123. Mirzabeigi MN, Au A, Jandali S, Natoli N, Sbitany H, Serletti JM. Trials and tribulations with the inferior gluteal artery perforator flap in autologous breast reconstruction. Plast Reconstr Surg. 128(6):614e-24e, 2011.
    124. Lanitis S, Tekkis PP, Sgourakis G, Dimopoulos N, Al Mufti R, Hadjiminas DJ. Comparison of skin-sparing mastectomy versus non-skin-sparing mastectomy for breast cancer: a meta-analysis of observational studies. Ann Surg. 251(4):632-9, 2010.
    125. Yi M, Kronowitz SJ, Meric-Bernstam F, et al. Local, regional, and systemic recurrence rates in patients undergoing skin-sparing mastectomy compared with conventional mastectomy. Cancer. 117(5):916-24, 2011.
    126. Romics L Jr, Chew BK, Weiler-Mithoff E, et al. Ten-year follow-up of skin-sparing mastectomy followed by immediate breast reconstruction. Br J Surg. 99(6):799-806, 2012.
    127. Endara M, Chen D, Verma K, Nahabedian MY, Spear SL. Breast reconstruction following nipple-sparing mastectomy: a systematic review of the literature with pooled analysis. Plast Reconstr Surg. 132(5):1043-54, 2013.
    128. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Breast cancer risk reduction V.2.2015. http://www.nccn.org/, 2015.
    129. American Cancer Society. After breast reconstruction surgery. http://www.cancer.org/Cancer/BreastCancer/MoreInformation/BreastReconstructionAfterMastectomy/breast-reconstruction-after-mastectomy-after-surgery, 2015.
    130. U.S. Department of Labor. Fact sheet: Women’s Health and Cancer Rights Act. http://www.dol.gov/ebsa/publications/whcra.html, 2014.
    131. Schnipper LE, Smith TJ, Raghavan D, et al. American society of clinical oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol. 30(14):1715-24, 2012.
    132. National Cancer Institute. General information about breast cancer and pregnancy. http://www.cancer.gov/types/breast/patient/pregnancy-breast-treatment-pdq, 2014.
    133. Litton JK and Theriault RL. Chapter 65: Breast cancer during pregnancy and subsequent pregnancy in breast cancer survivors, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
    134. Loibl S, Schmidt A, Gentilini O, et al. Breast cancer diagnosed during pregnancy: adapting recent advances in breast cancer care for pregnant patients. JAMA Oncol. 1(8):1145-53, 2015.
    135. Amant F, von Minckwitz G, Han SN, et al. Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J Clin Oncol. 31(20):2532-9, 2013.
    136. American Cancer Society. Breast Cancer Facts and Figures 2015-2016. Atlanta, GA: American Cancer Society, 2015.
    137. Partridge AH, Goldhirsch A, Gelber S, Gelber RD. Chapter 85: Breast Cancer in Younger Women, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition, Lippincott Williams & Wilkins, 2014.
    138. Partridge A, Gelber S, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Winer E. Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. Eur J Cancer. 43(11):1646-53, 2007.
    139. Jeruss JS, Woodruff TK. Preservation of fertility in patients with cancer. N Engl J Med. 360(9):902-11, 2009.
    140. Moore HC, Unger JM, Phillips KA, et al. for the POEMS/S0230 Investigators. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 372(10):923-32, 2015.
    141. Lambertini M, Boni L, Michelotti A, et al. for the GIM Study Group. Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial. JAMA. 314(24):2632-40, 2015.
    142. Munhoz RR, Pereira AA, Sasse AD, et al. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2(1):65-73, 2016.
    143. American Cancer Society. Breast cancer in men. http://www.cancer.org/Cancer/BreastCancerinMen/DetailedGuide/breast-cancer-in-men-key-statistics, 2015.
    144. American Cancer Society. Cancer Facts and Figures 2016. Atlanta, GA: American Cancer Society, 2016.
    145. Anderson WF, Jatoi I, Tse J, Rosenberg PS. Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol. 28(2):232-9, 2010.
    146. Jain S and Gradishar WJ. Chapter 61: Male breast cancer, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
    147. National Cancer Institute. Male breast cancer treatment. http://www.cancer.gov/types/breast/patient/male-breast-treatment-pdq, 2015.
    148. American Cancer Society. Can breast cancer in men be found early? http://www.cancer.org/cancer/breastcancerinmen/detailedguide/breast-cancer-in-men-detection, 2015.
    149. Howlader N, Noone AM, Krapcho M, et al., editors. SEER Cancer Statistics Review Fast Stats: Relative survival by survival time, 1988-2012. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/faststats/, 2016.
    150. Xu S, Yang Y, Tao W, et al. Tamoxifen adherence and its relationship to mortality in 116 men with breast cancer. Breast Cancer Res Treat. 136(2):495-502, 2012.
    151. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 353(5):487-97, 2005.
    152. National Cancer Institute. Questions to ask your doctor about treatment clinical trials. http://www.cancer.gov/about-cancer/treatment/clinical-trials/questions, 2012.
    153. American Cancer Society. Making treatment decisions: Clinical trials-what you need to know. http://www.cancer.org/acs/groups/cid/documents/webcontent/003006-pdf.pdf, 2014.
    154. Reich M, Lesur A, Perdrizet-Chevallier C. Depression, quality of life and breast cancer: a review of the literature. Breast Cancer Res Treat. 110(1):9-17, 2008.
    155. Schreiber JA, Brockopp DY. Twenty-five years later--what do we know about religion/spirituality and psychological well-being among breast cancer survivors? A systematic review. J Cancer Surviv. 6(1):82-94, 2012.
    156. Cherny NI and Truong PT. Chapter 79: Brachial plexopathy in patients with breast cancer, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
    157. Vilholm OJ, Cold S, Rasmussen L, Sindrup SH. The postmastectomy pain syndrome: an epidemiological study on the prevalence of chronic pain after surgery for breast cancer. Br J Cancer. 99:604-610, 2008.
    158. Schmitz KH, Speck RM, Rye SA, DiSipio T, Hayes SC. Prevalence of breast cancer treatment sequelae over 6 years of follow-up: the Pulling Through Study. Cancer. 118(8 Suppl):2217-25, 2012.
    159. Kraus-Tiefenbacher U, Sfintizky A, Welzel G, et al. Factors of influence on acute skin toxicity of breast cancer patients treated with standard external beam radiotherapy (EBRT) after breast conserving surgery (BCS). Radiat Oncol. 7(1):217, 2012.
    160. National Cancer Institute. Pain control: Support for people with cancer. http://www.cancer.gov/publications/patient-education/paincontrol.pdf, 2014.
    161. American Cancer Society. Developing a pain control plan. http://www.cancer.org/treatment/treatmentsandsideeffects/physicalsideeffects/pain/developing-a-pain-control-plan, 2015.
    162. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Adult cancer pain V.2.2015. http://www.nccn.org/, 2015.
    163. Chan A, Delaloge S, Holmes FA, et al. for the ExteNET Study Group. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 17(3):367-77, 2016.
    164. Goss PE, Ingle JN, Pritchard KI, et al. Aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med. 375(3):209-19, 2016.  
    165. Lu W, Cui Y, Chen X, et al. Changes in quality of life among breast cancer patients three years post-diagnosis. Breast Cancer Res Treat. 114(2):357-69, 2009.
    166. Shapiro SL, Lopez AM, Schwartz GE, et al. Quality of life and breast cancer: relationship to psychosocial variables. J Clin Psychol. 57(4):501-19, 2001.
    167. Perkins EA, Small BJ, Balducci L, Extermann M, Robb C, Haley WE. Individual differences in well-being in older breast cancer survivors. Crit Rev Oncol Hematol. 62(1):74-83, 2007.
    168. Park JW, Liu MC, Yee D, et al for the I-SPY 2 Investigators. Adaptive randomization of neratinib in early breast cancer. N Engl J Med. 375(1):11-22, 2016.
    169. Esserman LJ and Joe BN. Clinical features, diagnosis, and staging of newly diagnosed breast cancer, in Up-to-Date (Burstein H, Vora SR, eds.). Up-to-Date, 2016.
    170. U.S. Food and Drug Administration. Information for consumers (biosimilars). http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm241718.htm, 2015.
    171. Rugo HS, Barve A, Waller CF, et al. for the Heritage Study Investigators. Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: a randomized clinical trial. JAMA. 317(1):37-47, 2017. 
    172. American Cancer Society. Cancer Facts and Figures 2017. Atlanta, GA: American Cancer Society, 2017.

    Updated 01/25/17


    Treatment Home 





1-877 GO KOMEN